DCTH

#2702
Delcath Systems, Inc. - Common Stock
10.7 8 USD
+9744.75%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
10.78
10.78
Range Annuel
0.11
12.27
Changement quotidien
+9744.75%
Changement Mensuel
+5.27%
Evolution sur 6 mois
+13.24%
Changement Annuel
+4.26%
Clôture Précédente
0.1 1
Open
10.7 8
Low
10.7 8
High
10.7 8
Volume
62
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 372.14 M
  • Employee 156
  • Founded 1988
  • CEO Gerard Michel
  • Website www.delcath.com
  • Headquarter Delaware, United States
  • FIGI BBG000BY2VF5
  • Industry Dispositifs Médicaux
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
144.29
ratio cours/chiffre d'affaires
4.73

Delcath Systems, Inc. - Common Stock

Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.

Nouvelles